<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01197118</url>
  </required_header>
  <id_info>
    <org_study_id>TJCC-GC001</org_study_id>
    <nct_id>NCT01197118</nct_id>
  </id_info>
  <brief_title>Postoperative Sequence Chemoradiotherapy Compared With Chemotherapy Alone for Advanced Gastric Cancer</brief_title>
  <official_title>Phase 2 Study of Chemoradiotherapy for Advanced Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huazhong University of Science and Technology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gastric cancer is one of the most prevalent malignancies in China; the survival rate remains
      poor despite potentially curative resections. Complete surgical resection is the only
      potentially curative therapy available to patients with gastric cancer. However, even after a
      complete resection with negative margins, many patients will experience recurrence. In recent
      years, the radiation therapy in the carcinoma of the stomach represents a new issue that
      should be addressed accompanying the development of radial physics and radial biology, the
      clinical application of computed tomographic (CT) simulation and digital reconstitution
      technique, especially the application of 3-dimensional conformal and intensity modulated
      radiation therapy. Radiation therapy plus concurrent chemotherapy has been demonstrated to
      cause a significant improvement in overall and disease-free survival according to Intergroup
      Trial 0116/SWOG 9008. So the investigators designed the trial to see whether a postoperative
      sequence chemoradiotherapy including oxaliplatin fluorouracil-based regimen can improve
      survival for advanced gastric cancer.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">May 2011</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>chemotherapy alone following radical resection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sequence chemoradiotherapy following radical resection</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>sequence chemoradiotherapy</intervention_name>
    <description>Postoperative radiotherapy regimen: Therapy plan system was formulated by Computed tomographic (CT) simulation. Radiation was delivered with 15MV photons. Radiotherapy consisted of 4500 cGy of radiation at 180 cGy per day, five days per week for five weeks, to the tumor bed, to the margins of resection or the stoma, to the regional nodes. Protection of spinal cord, heart, liver and kidney should be considered.
Postoperative chemotherapy regimen: see arm 2</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy alone following radical resection</intervention_name>
    <description>Postoperative chemotherapy regimen: The OLF regimen was administrated: Oxaliplatin, 130 mg/m2/day on day1, i.v. 2 h; fluorouracil, 425 mg/m2/day on day1~5, i.v.; leucovorin, 200 mg/m2/day on day 1~5, i.v.; every 21 days repeated, for 6 cycles.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Postoperative histologically confirmed advanced adenocarcinoma of the stomach or the
             gastroesophageal junction.

          2. Age of 18 to 75, Karnofsky score higher than 70.

          3. Postoperative histologically conformed metastasis in perigastric lymph nodes and/or
             tumor invasion to muscularis propria or subserosa, with or without positive incisal
             margin.

          4. No severe functional damage of major organ, normal blood cell, normal liver and kidney
             function.

          5. No clinical findings of distant metastasis.

          6. Predictive survival time longer than 6 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shiying Yu, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tongji Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qiang Fu, Master</last_name>
    <phone>86-27-63089811</phone>
    <email>yunr777@yahoo.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tongji Cancer Center,Tongji Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qiang Fu, Master</last_name>
      <phone>86-27-83663342</phone>
      <email>yunr777@yahoo.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Shiying Yu, Master</last_name>
      <phone>86-27-83663342</phone>
      <email>syyu@tjh.tjmu.edu.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Shiying Yu, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Qiang Fu, Master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Xiang-Lin Yuan, Qiang Fu ,Shi-Ying Yu .Postoperative sequence chemoradiotherapy for advanced gastric cancer:an analysis of 36 cases.World Chinese Journal of Digestology,2007(36):3856-3859.</citation>
  </reference>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2009</study_first_submitted>
  <study_first_submitted_qc>September 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2010</study_first_posted>
  <last_update_submitted>September 8, 2010</last_update_submitted>
  <last_update_submitted_qc>September 8, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2010</last_update_posted>
  <responsible_party>
    <name_title>Shiying Yu / Chief</name_title>
    <organization>Tongji Cancer Center</organization>
  </responsible_party>
  <keyword>gastric cancer</keyword>
  <keyword>sequence chemoradiotherapy</keyword>
  <keyword>OLF regimen</keyword>
  <keyword>survival rate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

